Merck Completes Women's Health Organon Spinoff

by Vandana Singh, Benzinga Editor

June 3, 2021 12:42 PM | 1 min read |

In a move to free up a cash windfall and streamline the business, Merck & Co Inc MRK had long planned to slice away its women’s health business into a standalone spinoff.
As of Thursday, that spinoff, dubbed Organon, is now a public entity all its own. Organon & Co. OGN debuted on the NYSE.
As a part of the spinoff, Merck will receive a $9 billion special tax-free dividend that it will use for a future acquisition.
Organon is focused on Nexplanon, a long-active reversible contraceptive that has a patent expiring in 2027.
Last year, its sales were around $680 million. The company said it could boost sales to more than $1 billion in 2021.
Price Action: MRK shares are down 3.3% at $73.36, while OGN is down 4.6% at $33.63 during the market session on the last check Thursday.

Posted In: Biotech M&A News Health Care General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.